Incyte Approval In Subset Of Cholangiocarcinoma May Lead To Bigger Opportunities
Executive Summary
Biotech hopes this initial approval will be followed by approvals of Pemazyre in bladder cancer, first-line cholangiocarcinoma and possibly even a tumor-agnostic indication for FGFR-mutated cancers.
You may also be interested in...
Taiho’s Lytgobi Faces Heavy Competition, But Sets Efficacy Bar For Now
The FGFR inhibitor beats prior entrants on efficacy in cholangiocarcinoma, although Relay presented data at ESMO for its investigational RLY-4008 showing especially high efficacy and tolerability.
ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma
The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.
Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker